The France High-Throughput Screening (HTS) Market was valued at $571.4 Million in 2026 and projected to reach to $741.2 Million by 2031, representing a compound annual growth rate of 9.0%. France's High-Throughput Screening market is poised for sustained growth through 2031, driven by increased R&D spending in pharmaceutical development and a growing emphasis on precision medicine.
France's High-Throughput Screening market is valued at USD 571.4 million in 2026, with a projected growth to USD 741.2 million by 2031, representing a robust 9% CAGR. This growth trajectory reflects France's strengthening position in European pharmaceutical research and development.
French pharmaceutical and biotechnology companies are increasingly investing in automated screening technologies to accelerate drug discovery processes. This shift is driving demand for advanced HTS platforms and integrated laboratory automation solutions across major research hubs.
France's commitment to life sciences innovation, supported by government funding and private sector investment, is expanding HTS capabilities in academic institutions and commercial laboratories. Key clusters in Paris, Lyon, and Marseille are becoming centers of excellence for screening technologies.
The French HTS market features a mix of international vendors and emerging local solution providers. Strategic partnerships between French biotech firms and global screening technology leaders are accelerating market penetration and innovation in the region.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | LIQUID HANDLING SYSTEMS (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.7% from 2026 to 2031 |
| Largest Segment | NORTH AMERICA (Type) |
| Market Size Base Year (Billions) | ~USD 27.61 (2026) |
| Revenue Forecast (Billions) | ~USD 45.9 (2031) |
| Segments Covered | Type, Application, Technology |
3 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOCARTIS SA | Belgium | Private Company | Oncology assay consumables,Instrument systems and service,Other legacy and residual activities, |
| QIAGEN NV | Netherlands | Public Company | Sample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health, viral load),PCR and enzyme solutions (qPCR, dPCR, RT-PCR, configured enzymes), |
| CODEXIS, INC. | United States | Public Company | CodeEvolver platform-enabled enzyme sales and services,ECO Synthesis platform for RNAi and nucleic acid manufacturing,Licensing and royalties from technology partnerships, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing, single-use, filtration, aseptic fill-finish),Life Sciences (analytical instruments, genomics, lab automation),Diagnostics (clinical instruments, consumables, software, services), |
| MERCK KGAA | Germany | Public Company | Life Science,Healthcare,Electronics, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| REVVITY, INC. | United States | Public Company | Diagnostics (prenatal, neonatal, infectious disease, immunodiagnostics),Life science reagents and assays (BioLegend, Dharmacon, Alpha platforms),Instruments and imaging systems, |
| TECAN GROUP LTD. | Switzerland | Public Company | Liquid handling and automation platforms (incl. Tecan Labwerx),Microplate readers, washers, and detection instruments,Consumables, sequencing reagents, immunoassays, and antibodies, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics systems, kits, and quality controls,Life Science instruments and reagents,Informatics and software, |
| CORNING INCORPORATED | United States | Public Company | Optical communications (fiber, cable, hardware, connectivity),Display glass substrates (LCD and OLED),Specialty materials and mobile consumer electronics glass, |
| METTLER-TOLEDO INTERNATIONAL INC. | Switzerland | Public Company | Laboratory instruments and LabX software,Industrial instruments and product inspection,Retail weighing and fresh-goods solutions, |
| LONZA GROUP | Switzerland | Public Company | Integrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA), |
| WATERS CORPORATION | United States | Public Company | Liquid Chromatography Systems and Columns,Mass Spectrometry Systems,TA Instruments (Thermal, Rheometry, Calorimetry), |
| SARTORIUS AG | Germany | Public Company | Bioprocess solutions (bioreactors, filtration, chromatography, fluid management),Lab products and services (weighing, pipettes, filtration, microbiological testing),Advanced analytical and cell analysis systems (BLI, SPR, cytometry, live-cell imaging), |
| EPPENDORF SE | Germany | Private Company | Liquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors), |
| PORVAIR PLC | United Kingdom | Public Company | Aerospace & Industrial Filtration,Laboratory Instruments and Consumables,Metal Melt Quality (Porous Ceramic Filters), |
BIOCARTIS SA is a Belgian private company established in 2014 with 500 employees. The company focuses on molecular diagnostics and personalized medicine solutions.
QIAGEN NV is a Dutch public company founded in 1984 with 5,500 employees. The company is a leading provider of molecular diagnostics, sample preparation, and life sciences research tools.
CODEXIS, INC. is a United States public company founded in 2002 with 146 employees. The company develops enzyme engineering and biocatalysis solutions for pharmaceutical and industrial applications.
THERMO FISHER SCIENTIFIC INC. is a United States public company founded in 1956 with 125,000 employees. The company is a global leader in serving science with a broad portfolio of laboratory equipment, reagents, and services.
DANAHER CORPORATION is a United States public company founded in 1969 with 59,000 employees. The company operates a diversified conglomerate with significant presence in life sciences, diagnostics, and environmental solutions.
MERCK KGAA is a German public company founded in 1668 with 59,077 employees. The company is a global science and technology leader operating in pharmaceuticals, life sciences, and performance materials.
AGILENT TECHNOLOGIES, INC. is a United States public company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences, diagnostics, and applied chemical markets.
REVVITY, INC. is a United States public company founded in 1937 with 11,000 employees. The company develops and manufactures analytical instruments and software for life sciences research and diagnostics.
TECAN GROUP LTD. is a Swiss public company founded in 1980 with 3,166 employees. The company specializes in laboratory automation and detection solutions for life sciences and diagnostics applications.
BIO-RAD LABORATORIES, INC. is a United States public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research products and clinical diagnostics solutions.
CORNING INCORPORATED is a United States public company founded in 1851 with 67,200 employees. The company is a diversified technology leader with significant operations in life sciences, laboratory products, and specialty materials.
METTLER-TOLEDO INTERNATIONAL INC. is a Swiss public company founded in 1991 with 16,600 employees. The company manufactures precision instruments and services for laboratory, industrial, and retail applications.
LONZA GROUP is a Swiss public company founded in 1897 with 20,000 employees. The company is a leading supplier of products and services for the pharmaceutical, biotech, and specialty chemical industries.
WATERS CORPORATION is a United States public company founded in 1958 with 7,900 employees. The company develops and manufactures analytical instruments and software for laboratory and life sciences applications.
SARTORIUS AG is a German public company founded in 1870 with 14,242 employees. The company provides laboratory and process technologies for pharmaceutical, biotech, and food industries.
EPPENDORF SE is a German private company founded in 1945 with 4,358 employees. The company manufactures laboratory equipment and consumables for life sciences research and diagnostics.
PORVAIR PLC is a United Kingdom public company founded in 1982 with 992 employees. The company manufactures advanced filtration and separation products for life sciences and industrial applications.
Italy's HTS market is estimated at USD 571.4 million in 2026, with verified data reflecting the country's active investment in drug discovery infrastructure and automated screening technologies.
Italy's HTS market is forecast to reach USD 741.2 million by 2031, representing a 9.0% compound annual growth rate over the five-year forecast period.
Italy's HTS market growth is driven by increased R&D spending, adoption of automation in drug discovery, academic-industry partnerships, and demand for faster compound evaluation in therapeutic areas such as oncology and infectious disease.
Italy's HTS adoption is particularly strong in oncology, infectious disease, and personalized medicine research, where high-throughput screening directly supports clinical development and commercial success.
Italy's 9.0% CAGR reflects steady growth within the European HTS landscape, supported by the country's robust regulatory environment, skilled workforce, and strategic position as a pharmaceutical research hub.
This research study relied heavily on secondary sources, directories, and databases to identify and collect valuable information for analyzing the global high-throughput screening (HTS) market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the high-throughput screening (HTS) market. The secondary sources used for this study include World Health Organization (WHO), American Society for Clinical Laboratory Science (ASCLS), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), American Association for Clinical Chemistry (AACC), National Center for Advancing Translational Sciences (NCATS), American Society for Pharmacology and Experimental Therapeutics (ASPET), National Health Service (NHS), Pharmaceuticals and Medical Devices Agency (PMDA), European Medicines Agency (EMA), Society for Laboratory Automation and Screening (SLAS), European Bioinformatics Institute, and Center for Translational Research, among others. Corporate filings include annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data were collected and analyzed to determine the overall size of the global high-throughput screening (HTS) market, which was subsequently validated through primary research. These sources were also used to obtain key information on major players, market classification, and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess the market's future prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were employed to estimate and validate the overall size of the high-throughput screening (HTS) market. These methods were also widely used to determine the size of various market segments. The research methodology used to estimate the market size includes the following:

After estimating the overall market size, the total market was divided into segments and subsegments. Data triangulation and market breakdown techniques were used where applicable to finalize the overall market analysis and obtain precise statistics for all segments and subsegments. The data was triangulated by examining various factors and trends from both demand and supply sides.
High-throughput screening (HTS) is a drug discovery process that involves automated testing of large quantities of chemical or biological compounds against specific biological targets using various binding assays.
The HTS market comprises products (instruments, reagents & consumables, software), and services used to perform automated, parallel screening of large compound or biological libraries against defined biological targets or assays to identify active entities (hits). The high-throughput screening (HTS) market comprises workflow stages from assay development and compound library management to automated large-scale screening and hit identification, culminating in validated screening hits.
Based on the given market data, MarketsandMarkets offers customization to meet the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all High-Throughput Screening (HTS) Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report